Watson has signed a licensing agreement with GeneraMedix for the exclusive US marketing rights to a generic version of Ferrlecit (sodium ferric gluconate complex in sucrose injection). The drug is indicated for the treatment of iron deficiency anemia in hemodialysis patients receiving supplemental epoetin therapy.
GeneraMedix has filed an Abbreviated New Drug Application (ANDA) with the FDA for a sodium ferric gluconate complex in sucrose product, that is packaged in a vial.
Under the terms of the agreement, GeneraMedix will supply the product to Watson to market, sell and distribute it in the US.
New Jersey-based GeneraMedix is a pharmaceutical company that develops, markets and distributes generic injectable products.
Headquartered in California, Watson Pharmaceuticals develops, manufactures, markets and distributes brand and generic pharmaceutical products.